Teva Pharmaceutical Industries Ltd (TEVA)

TEVA (NYSE:Drugs) EQUITY
$17.19
pos +0.00
+0.00%
Today's Range: 17.05 - 17.32 | TEVA Avg Daily Volume: 20,222,700
Last Update: 09/22/17 - 4:00 PM EDT
Volume: 0
YTD Performance: -52.69%
Open: $0.00
Previous Close: $17.15
52 Week Range: $15.22 - $51.51
Oustanding Shares: 1,016,000,000
Market Cap: 17,424,400,000
6-Month Chart
TheStreet Ratings Grade for TEVA
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 3 2 4 4
Moderate Buy 0 0 1 1
Hold 14 14 10 10
Moderate Sell 0 0 0 0
Strong Sell 3 2 0 0
Mean Rec. 2.97 2.96 2.40 2.40
Latest Dividend: 0.07
Latest Dividend Yield: 5.48%
Dividend Ex-Date: 08/25/17
Price Earnings Ratio: 3.34
Price Earnings Comparisons:
TEVA Sector Avg. S&P 500
3.34 0.00 36.70
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-44.77% -65.95% -67.12%
GROWTH 12 Mo 3 Yr CAGR
Revenue 11.50 0.10 0.03
Net Income -80.50 -0.80 -0.37
EPS -96.20 -0.90 -0.64
Earnings for TEVA:
EBITDA 6.18B
Revenue 21.90B
Average Earnings Estimates
Qtr (09/17) Qtr (12/17) FY (12/17) FY (12/18)
Average Estimate $1.05 $1.12 $4.19 $3.92
Number of Analysts 5 5 7 7
High Estimate $1.06 $1.24 $4.32 $4.63
Low Estimate $1.03 $1.00 $4.06 $3.50
Prior Year $1.28 $1.36 $5.06 $4.19
Growth Rate (Year over Year) -18.28% -17.79% -17.11% -6.61%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands

Recommended Reading Real Money Pro($)

From Barron's online edition today, Teva Pharmaceuticals (TEVA)   could double.
Answering questions from the biotech mailbag.
Damage on TEVA's charts is significant.
There are two separate and positive developments at Allergan (AGN) over the last three days that should continue to buoy its shares, which were up $6 on Friday. 
Teva could be on the verge of a surge similar to what 3 other companies have seen since 2008-09.
Bearish
Aug 24, 2017 | 8:49 AM EDT
Credit Suisse downgraded Teva Pharmaceutical Industries to "Underperform" and lowered its price target to $13.
I am working incrementally into some small stocks with great long-term value.

Teva Is Cheap, Not Dead Real Money Pro($)

The drug stock deserved to go down, but the resulting selloff is an overreaction.

Think for Yourself Real Money Pro($)

If you want to reap big gains, read, understand and buy when the numbers make sense.
A couple of new prospects emerge.

Columnist Conversations

Equity futures were up slightly just before 9:30 PM Sunday night.
Spent a good amount of time with PayPal CEO Dan Schulman this week...and came away fully understanding why thi...
Has quietly taken a mini beating over the past few weeks. Might be worth a look on Monday given everything tha...

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.